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Abstract
Chronic myeloid leukemia (CML) is characterized by the presence of a constitutively active Abl kinase, which is the product
of a chimeric BCR-ABL gene, caused by the genetic translocation known as the Philadelphia chromosome. Imatinib, a
selective inhibitor of the Bcr-Abl tyrosine kinase, has significantly improved the clinical outcome of patients with CML.
However, subsets of patients lose their response to treatment through the emergence of imatinib-resistant cells, and
imatinib treatment is less durable for patients with late stage CML. Although alternative Bcr-Abl tyrosine kinase inhibitors
have been developed to overcome drug resistance, a cocktail therapy of different kinase inhibitors and additional
chemotherapeutics may be needed for complete remission of CML in some cases. Chlorambucil has been used for
treatment of B cell chronic lymphocytic leukemia, non-Hodgkin’s and Hodgkin’s disease. Here we report that a DNA
sequence-specific pyrrole-imidazole polyamide-chlorambucil conjugate, 1R-Chl, causes growth arrest of cells harboring both
unmutated BCR-ABL and three imatinib resistant strains. 1R-Chl also displays selective toxicities against activated
lymphocytes and a high dose tolerance in a murine model.
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Introduction
Chronic myeloid leukemia (CML) is characterized by the
presence of a constitutively active chimeric Bcr-Abl kinase. The
BCR-ABL chimeric gene arises from a genetic translocation
between the ABL proto-oncogene on chromosome 9 and the
breakpoint cluster region (BCR) on chromosome 22 [1,2,3]. In the
late 1990s, imatinib emerged as a single agent treatment for CML,
and was approved for first-line treatment of CML. Imatinib has
revolutionized treatment for this disease [4]. Patients who received
imatinib during the chronic phase have a very good prognosis with
survival rate of 89% by 60 months and freedom from progression
to accelerated phase (AP) or blast crisis (BC) of 93% [5,6].
However, imatinib responses are much less durable in patients
with AP or BC, and there is no single standard therapy for these
stages of CML [7,8,9]. Alternative Abl kinase-selective inhibitors
have been developed to overcome resistance to imatinib. Two
compounds in particular, dasatinib and nilotinib, inhibits 14 of out
of the 15 imatinib-resistant BCR-ABL mutants [10,11]. However,
dasatinib and nilotinib do not inhibit the mutant derived from the
T315I substitution; thus potential resistant mutations are still
possible.
Chlorambucil (Chl) is an effective first-line single-agent
treatment for chronic lymphocytic leukemia and as a combined
chemotherapeutic in low-grade non-Hodgkin’s and Hodgkins’
disease [12,13]. However, Chl has poor affinity toward its known
target DNA, with efficacy only at ,100 mM concentration
[14,15]. When conjugated to pyrrole-imidazole (Py-Im) polyam-
ides, Chl has shown increased affinity and specificity toward DNA
[16,17,18]. By screening a small library of polyamide-Chl
conjugates, we identified one specific conjugate, termed 1R-Chl
(Figure 1A), which blocks proliferation of various cancer cell lines
in culture. 1R-Chl has anti-tumor activity in mice bearing human
SW620 colon carcinoma, K562 CML, Calu-1 lung cancer and
22Rv1 prostate cancer xenografts [19,20]. Microarray analysis
indicated that limited numbers of genes are significantly down
regulated by 1R-Chl. One such gene encodes histone H4 (H4c),
and western blotting experiments confirmed that total H4 protein
levels are reduced in 1R-Chl treated cells. 1R-Chl is expected to
bind the general DNA sequence 59-WGGWGW-39, where W=A
or T., This sequence is found in the histone H4 gene, which is
bound by the parent compound lacking Chl and alkylated by 1R-
Chl. Alkylation within the coding region of the H4c gene was
confirmed in cell culture by ligation-mediated PCR. Such
alkylation leads to down-regulation of H4 gene expression, with
a concomitant loss of H4 protein. This leads to nucleosome
disruption, widespread alkylation within genomic DNA and cell
cycle arrest at G2/M. Changing the chirality of the ‘‘turn’’ amino
acid to S-2,4-diaminobutyric acid (1S-Chl) eliminates the biolog-
ical activity of the conjugate due to a loss of binding and alkylation
of this target DNA sequence. 1R-Chl has also been shown to
inhibit proliferation of the CML cell line K562 at nanomolar
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that do not target the H4c gene fail to down-regulate this gene or
block cell proliferation [19,20].
In this study, we investigated the effects of 1R-Chl, and in
combination with imatinib, on native and mutated BCR-ABL
transduced murine bone marrow (BM) cells. Studies were also
done using primary murine BM cells and mononuclear cells from
normal donors and CML patients. In addition, dosing experiments
of 1R-Chl have been examined in the murine model. Our results
suggest that 1R-Chl is effective in blocking proliferation of cells
harboring most of the common mutations found in Bcr-Abl
kinases. 1R-Chl also works additively with imatinib in murine BM
cells transduced with BCR-ABL. 1R-Chl only displayed growth
inhibition activity and toxicity against proliferating cells, while no
toxicity was found in non-cycling cells. In addition, 1R-Chl
displayed a high dose tolerance in the murine model, with liver
toxicity not observed until levels approaching ten times the
therapeutic dose were reached.
Results
Polyamide-Chl conjugates
For this study, we used 1R-Chl, ImIm-b-Im-a(R-2,4-DABA
Chl)-
PyPyPyPy-b-Dp (where Py is pyrrole, Im is imidazole, b is
b-alanine, Dp is dimethylaminopropylamine, and 2,4-DABA is
R-2,4-diaminobutyric acid, with a describing the amino acid
linking the hairpin polyamide and Chl describing the chlorambucil
substation at the 4-amino position), and its inactive stereoisomer
1S-Chl, where the turn amino acid is -a(S-2,4-DABA) (Figure 1A).
These compounds have been extensively characterized previously
[20,21,22].
1R-Chl inhibits the growth of bone marrow cells
transduced with BCR-ABL or Y253H, E255K, and T315I
BCR-ABL mutants
Murine bone marrow cells that were transduced with full-length
native BCR-ABL, or BCR-ABL with kinase domain Y253H,
E255K, and T315I point mutations, were treated with different
concentrations of 1R-Chl, 1S-Chl, imatinib, and dasatinib
(Fig. 1B). 1R-Chl showed titratable inhibition of murine BM
colony formation for the unmutated Bcr-Abl and all kinase
domain point mutations studied here. The IC50 for blocking cell
proliferation is approximately 250 nM, similar to the IC50 for
imatinib. The control polyamide 1S-Chl, the stereoisomer of 1R-
Chl, as expected, did not display any inhibitory activity up to
1000 nM.
1R-Chl inhibits colony formation by CML patient MNCs
and normal human MNCs
1R-Chl, 1S-Chl, and imatinib were tested against bone marrow
mononuclear cells from patients in chronic phase of CML. The
Figure 1. Chemical structure of 1R-Chl, imatinib, dasatinib, and their effects on BCR-ABL unmutated and mutated genes transduced
into murine BM cells. (A) 1R-Chl (left) targets the DNA sequences 59-WGGWGW-39. Bold, imidazole rings. imatinib (middle) targets Bcr-Abl kinase,
and dasatinib (right) targets 14 out of 15 Bcr-Abl mutants. (B) Murine BM cells transduced with unmutated BCR-ABL and single point mutation Y253H,
E255K, and T315I genes were tested for the effectiveness of 1R-Chl (125 nM to 1000 nM), 1S-Chl (500 nM and 1000 nM), imatinib (500 nM and
5000 nM; IC50=260 nM for the native BCR-ABL transduced cells) [6], and dasatinib (10 nM and 100 nM; IC50=0.8 nM for the native BCR-ABL
transduced cells) [6]. Triplicate experiments were done, and the numbers of colonies were quantified 7 days after initial plating.
doi:10.1371/journal.pone.0003593.g001
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factors (rh stem cell factor, rh IL-3, rh GM-CSF with or without
erythropoietin). Cells were exposed to 1R-Chl, 1S-Chl, and
imatinib at different concentrations (Fig. 2A). The results show
that exposing CML patient MNCs to 1R-Chl suppressed colony
formation in both CFU-GM and BFU-E assays, while 1S-Chl was
ineffective. Thus, 1R-Chl was effective against CML patient
MNCs with an observed IC50 less than 125 nM, and in the murine
BM experiments (Fig. 1). Potential non-specific toxicity of 1R-Chl
was observed with normal human MNCs (Fig. 2B); however, such
toxicity may be explained by the unusually high effectiveness of
1R-Chl against activated human MNCs.
Additive effects of 1R-Chl in combination with imatinib
The additive effects of 1R-Chl and imatinib were also studied in
BCR-ABL transduced murine BM, CML patient MNCs, and
normal human donor MNCs. Inhibition of colony formation by
1R-Chl and imatinib was additive in unmutated BCR-ABL-
expressing murine BM (Fig. 3A). In MNCs from CML patients
and normal blood donors, 1R-Chl was a stronger growth inhibitor
than imatinib, and it appeared that 1R-Chl treatment alone at
500 nM is sufficient to completely (.90%) inhibit colony
formation by these cells (Fig. 3B and 3C). The observed additive
effects of 1R-Chl and imatinib indicate that a cocktail of 1R-Chl
with imatinib could potentially increase the efficacy of imatinib
treatment and prevent the emergence of imatinib-resistant CML
cells. However, the strong colony formation inhibition of normal
human MNCs by 1R-Chl could potentially indicate a non-specific
toxicity response due to 1R-Chl. Further experiments on both
murine BM and normal human donor MNCs were done to
address this issue.
No significant cell toxicity observed for the resting
murine BM cells and human MNCs
To determine if the non-specific toxicity of 1R-Chl described
above was due to the activation of mononuclear cells, the following
assays were performed. Murine BM cells and human peripheral
blood lymphocytes (hPBLs) were harvested and treated with
different concentrations of 1R-Chl, without activation by growth
factors or mitogens. MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-car-
boxymethoxyphenyl)-2-(4-sulfonphenyl-2H-tetrazolium salt) cyto-
toxicity assays (Promega, WI), which examine the mitochondrial
activity of cells, were used to examine the metabolic state of the
cells. MTS is bio-reduced by the mitochondria into a colored
formazan product. This conversion is only accomplished by the
dehydrogenase enzymes in metabolically active cells. For either
resting murine BM or normal human donor MNCs, there is no
significant cytotoxicity observed after treatment with 1R-Chl at
concentrations ranging from 10 to 1000 nM, after incubation for
72 or 96 hours (Fig. 4A and 4B). These data indicate that 1R-Chl
does not exhibit toxicity against non-proliferating murine BM cells
and human MNCs, and the colony forming inhibition was
probably due to growth inhibition of proliferative cells.
1R-Chl is well tolerated in mice
The potential toxicity of 1R-Chl in vivo was examined by I.V.
injections in Balb/c mice. For the short-term dosing experiment,
mice given 3 single-dose injections at 2.25 mg/kg, 22.5 mg/kg or
225 mg/kg, were monitored for 24 hours. For long-term dosing
experiments, 3 lower doses of 1R-Chl were given at 0.75 mg/kg,
7.5 mg/kg, and 75 mg/kg, 3 times every other day for one week.
As summarized in Fig. 5A, only the regimen involving three
injections of 75 mg/kg 1R-Chl over one week was toxic, leading to
death 3–5 days after the last injection. The short-term experi-
mental mice showed no obvious signs of toxicity; however, there
were some inconsistent histology results, and most animals were
essentially normal, except for the four mice in the 75 mg/kg
regimen. The two animals that died prior to the end of the
treatment had pale, light red/brown livers. In addition, both the
livers and the spleens of all four of the 75 mg/kg 1R-Chl-treated
mice were small compared with either the low-dose 1R-Chl-
treated animals or PBS-recipients. Microscopically, the livers from
three of the four highest-dose animals had microvacuolar
hepatopathy (Fig. 5B), consistent with Reye-type syndrome of
Balb/c mice. However, and most importantly, at 7.5 mg/kg
treatment doses, where 1R-Chl completely inhibits xenograft
growth, no weight loss nor abnormal organ and tissue histology
were observed in the mice [19,20].
Discussion
We have previously shown that 1R-Chl exerts its anti-
proliferative effects on cultured cells, and in mouse xenograft
models for human cancer, through a two-hit mechanism: 1R-Chl
binds and alkylates members of the histone H4 gene family, and
causes down-regulation of histone gene transcription [19,20,23].
Depletion of histone protein, and concomitant loss of nucleosomes,
results in opening of the genome for wide-spread alkylation by 1R-
Chl, leading to cell cycle arrest [23]. Thus, the mechanism of
Figure 2. Effects of 1R-Chl on colony formation of CML patient
MNCs and normal human MNCs. (A) MNCs from CML patients were
cultured with rh stem cell factor, rh IL-3, rh GM-CSF with or without
erythropoietin which lead to CFU-GM or BFU-E cell lineages. The
experiments were done in duplicate with 1R-Chl ranging from 125 to
1000 nM, 1S-Chl at 500 and 1000 nM, and imatinib at 500 and 5000 nM.
The colonies were counted and results were calculated as the
percentage of the control plates (without treatment) after 2 weeks.
(B) MNCs from normal donors were cultured and plated under the same
condition as CML patient cells. The cells were exposed to 500 and
1000 nM 1R-Chl, 500 and 1000 nM 1S-Chl, and 500 and 5000 nM
imatinib. The colonies were counted and percent growth inhibition was
calculated after 2 weeks.
doi:10.1371/journal.pone.0003593.g002
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Murine BM cells transduced with unmutated BCR-ABL were treated with
500 nM imatinib, 500 nM 1R-Chl, and 500 nM 1S-Chl individually, or in
combination of either 500 nM 1R-Chl or 500 nM 1S-Chl with 500 nM
imatinib. (B) Same treatment routines were used on CML patient MNCs.
The CML patient MNCs were treated 500 nM imatinib, 500 nM 1R-Chl,
and 500 nM 1S-Chl individually, or 500 nM 1R(S)-Chl in combination
with 500 nM imatinib. (C) Same experiments were done on normal
blood donor MNCs.
doi:10.1371/journal.pone.0003593.g003
Figure 4. Cytotoxicity (MTS) assays on resting murine BM cells
and human MNCs. (A) Ficoll-Hypaque-separated murine BM cells
were plated in triplicate with 1R-Chl (10, 100, 500, and 1000 nM)
without any growth factors or mitogens. After 72 and 96 hours, 20 mL
of Celltiter 96 Aqueous One solution (Promega, WI) was added. The
absorbances of the MTS metabolites were read corresponding to the
numbers of metabolically active cells. (B) Ficoll-Hypaque-separated
human MNCs were treated as above, and the viabilities of the cells were
assessed after 72 and 96 hours.
doi:10.1371/journal.pone.0003593.g004
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PLoS ONE | www.plosone.org 4 October 2008 | Volume 3 | Issue 10 | e3593Figure 5. Pharmacotoxicity of 1R-Chl and 1S-Chl in mice. (A) After single I.V. bolus injection of 1R-Chl at 2.25, 22.5, or 225 mg/kg, and PBS into
Balb/c mice, the mice were subjected to gross anatomical observation followed by detailed histological analysis (Left). Mice were also injected with
1R-Chl with the indicated dose (0.75, 7.5, and 75 mg/kg) three times in one week. Half of the experimental population was euthanized after 24 h, and
the other half after 7 days (as indicated). Animals were subjected to gross behavioral and anatomical observation followed by a detailed histological
analysis (Right). (B) Toxic doses of 1R-Chl can cause microvacuolar hepatopathy. Mice were subjected to the toxicity studies, including injections of a
dose-regime ten times higher than the therapeutic dose-regime. Representative tissues, including liver, were fixed in 10% formalin, trimmed for
histology, embedded in paraffin, 3.0 micron sections were cut, mounted on glass slides and stained with H&E. Photomicrographs of H&E sections
from liver of animals that received PBS and euthanized 7 days post-treatments (control), 3675 mg/kg and euthanized 24 h post-treatment, and
3675 mg/kg and euthanized 7 days post-treatments were shown (indicated above each picture). Morphology of the section is indicated below each
picture.
doi:10.1371/journal.pone.0003593.g005
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treatment of unmutated BCR-ABL and mutated BCR-ABL
transduced murine cells as well as primary CML cells from
patients with 1R-Chl alone or in combination with imatinib.
Previous studies have shown that growth inhibition of the CML
cell line K562 by 1R-Chl is independent of Bcr-Abl kinase
pathways [20]. Thus, the initial focus of this study was to test the
efficacy of 1R-Chl against unmutated BCR-ABL and three BCR-
ABL mutants. 1R-Chl has broad range inhibitory activity against
BCR-ABL positive cells and the three mutants under investigation.
Of particular interest, 1R-Chl shows comparable anti-proliferative
activity on BM cells transduced with the T315I mutant, which is
resistant to the imatinib and dasatinib treatment, compared to
unmutated BCR-ABL. This result is somewhat expected because
1R-Chl inhibits leukemia growth through the down-regulation of
the histone H4 transcription and its protein products [19,20]. We
have argued previously that 1R-Chl exerts its anti-proliferative
activity through a two-hit mechanism, wherein the primary effect
of the compound is to alkylate and down-regulate expression of
particular histone genes, including H4c and H4j/k in CML cells
[23]. Loss of histone protein leads to nucleosome loss, genome
opening, widespread DNA alkylation and subsequent cell cycle
arrest. None of these pathways are known to involve the Bcr-Abl
kinase.
Additive effects of the two drugs have been observed when 1R-
Chl is used in combination with imatinib. In murine cells
transduced with the BCR-ABL fusion gene, the effects of 1R-
Chl and imatinib on cell growth inhibition are additive and are
more effective than either single drug treatment. The combined
effects of 1R-Chl and imatinib are harder to judge in the primary
cell assays due to the observed increase in potency of 1R-Chl
against primary cells. However, there still appears to be additivity
when the combined treatments were used. These results indicate a
cocktail treatment of 1R-Chl in combination with imatinib could
potentially be an effective treatment for CML and prevent or delay
drug resistance.
The inhibitory potency of 1R-Chl has also been tested on
primary cells from CML patient MNCs and normal blood donors.
Titratable growth inhibition is observed in the CML patient
MNCs treatments while the control polyamide 1S-Chl is
ineffective. Throughout this investigation, it also appeared that
1R-Chl is a stronger inhibitor against MNCs from CML patients
(IC50,125 nM) than transduced murine cells (IC50,250 nM).
One alarming aspect, however, is that 1R-Chl also blocks the
proliferation of stimulated normal human donor MNCs. To
address the possibility of non-specific toxicity, 1R-Chl has been
tested against resting primary cells from both human and murine
sources. 1R-Chl only inhibited cell growth of proliferating cells
and no non-specific toxicity was observed in resting primary cells,
as judged by MTS assays for mitochondrial function. When cells
are not proliferating, 1R-Chl has little effect, which is consistent
with the proposed mechanism of action of 1R-Chl (through down-
regulation of H4 genes, thus inhibiting cell division).
To further investigate potential toxicity of 1R-Chl, murine
dosing experiments were performed on normal BALB/cByJ mice,
and they have shown surprisingly high dose tolerance for 1R-Chl.
All mice survived 24 hours post injection, even at 10 times the
normal treatment doses (225 mg/kg single dosing or 75 mg/kg at
three injections in one week). With the exception of mice that
received the highest doses (75 mg/kg), no obvious changes or
abnormalities in organ appearance were noted. This is consistent
with previous xenograft experiments (SW620 and K562 cell lines),
in which athymic nude mice were treated at (7.5 mg/kg per dose)
three doses every other day over 1 week via tail vein injections
[19,20]. Only those mice that received high doses (a 225 mg/kg
single dose or three doses of 75 mg/kg over 1 week) showed liver
anomalies and microvacuolar hepatopathy on microscopic
observation of liver slices. With the exception of the high dose
animals, there was also no significant weight loss. In previous
studies, a diastereomer of 1R-Chl (where the hairpin turn amino
acid is c-diaminobutyric acid), targeting the same sequence as 1R-
Chl but unable to discriminate single base pair mismatches, is
lethal under the same treatment conditions within 24 hours while
1R-Chl treated mice maintained their weight and behave
normally. These data indicate, at least in the small animal model,
1R-Chl unlike other potent DNA alkylating agents is very well
tolerated [19,20,21,24,25].
Selective Bcr-Abl tyrosine kinase inhibitor imatinib (STI 571,
Gleevec, Novartis) as the frontline therapeutic for CML has been a
major advance in cancer therapy [26,27]. However, many
resistance mutations to imatinib and the acquisition of Bcr-Abl-
independent genetic abnormalities during the course of treatment
have been reported [28,29,30,31,32]. Thus, development of
additional therapeutic approaches for CML and other malignan-
cies is worthwhile. 1R-Chl is capable of inhibiting K562 CML cell
growth both in vitro and in vivo. 1R-Chl is also highly effective in
blocking K562 xenograft growth, with high dose tolerance in the
murine model. Polyamide-Chl conjugates appear to be promising
cancer therapeutics. In addition, the inhibitory mechanism of 1R-
Chl in K562 cells is likely to be independent of BCR-ABL because
no significant down-regulation of BCR-ABL transcripts was
observed in either Affymetrix genechip analysis or real time
qRT-PCR [20]. Based on the findings of this study, these results
suggest 1R-Chl could be very effective against CML alone or in
combination with imatinib. Also, 1R-Chl is very effective against
imatinib resistant Bcr-Abl mutants including T315I, which is
resistant to all other Bcr-Abl kinase inhibitors including dasatinib.
The overall chemotherapeutic treatments are more effective when
1R-Chl and imatinib are used in combination and the effects
appeared to be additive. Most importantly, 1R-Chl is the first
sequence specific DNA alkylator reported to show little animal
toxicity at mid to high mg/kg range with 3 consecutive injections
every other day over 5 days. No behavior or significant weight
changes have been observed during normal Balb/c and xenograft
mice experiments [19,20,21]. Tallimustine and Brostallicin,
micromolar DNA alkylators targeting AT rich sequences, have
both reported significant animal toxicity at 4 mg/kg and 0.8 mg/
kg respectively [24,25]. These results suggest that the use of 1R-
Chl in combination with imatinib and other kinase inhibitors or
anti-cancer chemotherapeutics could potentially overcome the
potential resistance issues in CML.
Materials and Methods
Reagents
1R-Chl and 1S-Chl were synthesized at the Scripps Research
Institute and the California Institute of Technology as previously
described [16,21]. Imatinib was purchased from the Oregon
Health & Science University pharmacy. 1R-Chl and 1S-Chl were
prepared as 1 mmol/L stock solutions in water, and imatinib was
prepared as a 10 mmol/L stock in PBS. Experiments were
performed with dilutions of the initial stock solutions.
Murine BM cell colony-forming assays
To examine the efficacy of 1R-Chl against BCR-ABL
transduced primary cells, murine BM cells were pre-stimulated
with IL-3, IL-6, and SCF. The BM cells were than transduced
twice with 1610
6 plaque-forming units of murine stem cell
DNA Alkylators & Leukemia
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(E255K, Y253H, and T315I) [33]. The cells were then plated in
Methocult (5610
4 per plate) without cytokines in the absence or
presence of 1R-Chl (125 to 1000 nM), 1S-Chl (500 and 1000 nM),
and imatinib (500 and 5000 nM), and dasatinib (10 and 100 nM).
The numbers of colonies were quantified 7 days after plating.
CML patient and normal donor mononuclear cell (MNCs)
colony forming assays
Colony-forming assays were performed on primary cells from
CML patients and normal donor blood. The cells were incubated
in the presence of recombinant human (rh) stem cell factor (50 ng/
mL), 10 ng/mL rh GM-CSF, and 10 ng/mL rh interleukin-3 (IL-
3) for assessment of granulocyte-macrophage colony-forming unit
(CFU-GM) cells or with erythropoietin for assessment of blast
forming unit erythroid (BFE-E). In brief, Ficoll-Hypaque-separat-
ed cells were plated in duplicate in methylcellulose medium with
cytokines as described (IL-3, GM-CSF, SCF, and +/2EPO) at
5610
4/mL with different concentration of 1R-Chl, 1S-Chl, and
imatinib. After 2-week incubation at 37uC, BFU-E and CFU-GM
colonies were counted and results were expressed as the
percentage compared to the number of colonies on control plates.
Cell viability assays on resting murine BM cells and
human blood mononuclear cells
Murine BM cells and human MNCs were plated at 50,000 cells
per 100 mL. The cells were then treated with 1R-Chl at 10, 100,
500, and 1000 nM, under standard conditions (RPMI 1640 with
20% FBS) without stimulation by growth factors or mitogens.
After 72 and 96 hours, 20 mL Celltiter 96 Aqueous One Solution
Cell Assay (Promega, WI) was added. After a 4 hour incubation
period, the absorbance was read at 490 nm on a Tecan Infinite
200 plate reader (Tecan Systems Inc. San Jose, CA).
Pharmacotoxicity of 1R-Chl in mice
1R-Chl toxicities were also examined by I.V. tail vein injections
of 1R-Chl at three concentrations followed by either a short-term
or long-term experimental protocol. For the short-term studies, the
mice were given single-dose injections at 2.25 mg/kg, 22.5 mg/kg
or 225 mg/kg via tail vein. For the long-term experiments, 3 lower
doses of 1R-Chl were given at 0.75 mg/kg, 7.5 mg/kg, and
75 mg/kg, 3 times every other day throughout one week via tail
vein. The 7.5 mg/kg per-injection, 3 times every other day for one
week, was the effective treatment routine for previous xenograft
studies [19,20]. For all studies, the behavior and weight of the mice
were monitored, and the histology of major organs and tissues was
analyzed 24 hours after the last injection. For the long-term
experiments, the histology was done either 24 hours after or one
week after the last injection.
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